# AETHERA

Source: https://onco.cc/trials/aethera/  
OnCo record `aethera` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In AETHERA, a year of the CD30 ADC after transplant halved relapse risk in high-risk patients.

## Summary

AETHERA, trial NCT01100502 sponsored by Seagen and published in the Lancet in 2015, showed that a year of the CD30 antibody-drug conjugate brentuximab vedotin after autologous transplant halved the risk of relapse in high-risk Hodgkin lymphoma. It randomised 329 patients to brentuximab consolidation or placebo and met its primary progression-free survival endpoint with a large effect, while overall survival did not differ because of crossover, leading to approval in August 2015 as post-transplant consolidation. OnCo links it to Hodgkin lymphoma, autologous transplant and brentuximab vedotin. Now that brentuximab and PD-1 blockade are used before transplant, whether consolidation still adds anything is the open question.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT01100502
- Phase: 3
- Setting: High-risk Hodgkin lymphoma after autologous transplant: brentuximab vedotin consolidation vs placebo
- Sponsor: Seagen
- Enrolled: 329
- Result: PFS HR 0.57.
- Outcomes: Progression-free survival (median): Brentuximab vedotin 42.9 months vs Placebo 24.1 months, HR 0.57

## Sources

- ClinicalTrials.gov NCT01100502: https://clinicaltrials.gov/study/NCT01100502

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Relapsed and refractory classical Hodgkin lymphoma](https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/)
- technologies: [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- terms: [Maintenance and consolidation in lymphoma: where it works and where it does not](https://onco.cc/terms/lymphoma-tx-maintenance/)
- key papers: [AETHERA: brentuximab vedotin consolidation after autologous stem cell transplantation in Hodgkin lymphoma at risk of relapse](https://onco.cc/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/)

---
JSON: https://onco.cc/api/v1/entities/aethera.json